Self Administration clinical trials

Explore recruiting self administration clinical trials.

Recruiting self administration studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Self Administration trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

Self-administration of subcutaneous Elranatamab in the patients’ homes (ERICA) - An open label, phase two, prospective, non-randomized, sponsor-initiated multi center feasibility study

Denmark

Therapeutic exploratory (Phase II) EU CTIS Study details

A MULTICENTER, OPEN-LABEL, OUTPATIENT STUDY TO EVALUATE THE SAFE AND EFFECTIVE USE OF A ZILUCOPLAN AUTO INJECTOR COMBINATION PRODUCT FOR SUBCUTANEOUS SELF-ADMINISTRATION BY STUDY PARTICIPANTS WITH GENERALIZED MYASTHENIA GRAVIS

Poland

Therapeutic confirmatory (Phase III) EU CTIS Study details

Multi-center, double-blind, randomized, placebo-controlled, parallel-group study to evaluate the efficacy and safety of self-administered subcutaneous selatogrel for prevention of all-cause death and treatment of acute myocardial infarction in subjects with a recent history of acute myocardial infarction

Austria, Netherlands, Denmark, Poland, Romania, Slovakia +17 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

An Open-Label, Rater-Blind, Randomized, Multi-Center, Parallel-Arm, Active-Comparator Study to Assess the Efficacy and Tolerability of Ofatumumab 20mg SC monthly vs. First Line DMT - physician’s choice in the treatment of newly diagnosed RMS (STHENOS)

France, Germany, Italy, Spain

Therapeutic confirmatory (Phase III) EU CTIS Study details

A phase III, international, multiCenter, randomized, paraLlel-group, Endoscopist-blinded non-inferiority study of the efficAcy, safety and patient acceptance of mannitol veRsus Plenvu® in boWel prepAration for elective colonoscopY. CLEARWAY

Belgium, Spain, Sweden, Poland, Italy

Therapeutic confirmatory (Phase III) EU CTIS Study details

A three-year, multi-center, double-blind, extension study to evaluate the long-term safety and efficacy of ligelizumab in patients who completed ligelizumab’s Phase III studies in food allergy

Netherlands, France, Spain, Italy, Germany

Therapeutic confirmatory (Phase III) EU CTIS Study details

Self Administration trials by city

Self Administration in Toronto Self Administration in Vancouver Self Administration in Montreal Self Administration in Calgary Self Administration in Edmonton Self Administration in Ottawa Self Administration in Winnipeg Self Administration in Quebec City Self Administration in Hamilton Self Administration in Kitchener Self Administration in London Self Administration in Halifax Self Administration in New York Self Administration in Los Angeles Self Administration in Chicago Self Administration in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease